BioSpace News Archive

jCyte Inc ., a biotech company dedicated to improving the lives of patients with rare degenerative retinal diseases, announced today its Scientific Advisory Board (SAB) comprised of world-renowned retinal physicians to provide external scientific review and high-level counsel on the Company’s research and development programs. The SAB will continue to work closely with the jCyte leadership team, as the Comp

Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, announced the closing of its previously announced underwritten public offering of 8,625,000 shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional 1,125,000 shares, at a price to

Ancora Heart, Inc. , a company developing a novel therapy to address heart failure, today announced U.S. Food and Drug Administration (FDA) approval of its Investigational Device Exemption (IDE) application for the CorCinch-HF pivotal study, which is designed to evaluate the safety and e

Unique Combination of Proprietary Technologies for Innovative Tumor Processing Workflow Expected to Accelerate Cancer R&D with Expanded IDs of Critical Disease State Biomarkers with Higher Precision and Speed

CES Innovation Awards Winner NextMind Opens Public Preorders for Wearable Brain-Sensing DevKit

Nordic Nanovector ASA announces that it will amend the trial protocol for its PARADIGME trial to broaden the inclusion criteria and expand the pool of eligible patients with the aim of increasing the present rate of enrolment.

During June 2020, the registered number of shares and votes in Moberg Pharma AB has increased due to conversion of convertible notes issued pursuant to the financing agreement entered into between the Company and Nice & Green S.A. on March 23rd, 2020.

Oncopeptides AB announces that the Company submits a New Drug Application to the U.S. FDA, for accelerated approval of melflufen in combination with dexamethasone for the treatment of adult patients with multiple myeloma whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent and one anti-CD38 monoclonal antibody.

IRRAS AB, a commercial stage medical technology company with a comprehensive portfolio of innovative products for neurocritical care, provided an update on the launch of its IRRAflow® and Hummingbird ICP Monitoring product lines during the evolving global COVID-19 pandemic.

TLC, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need in pain management, ophthalmology and oncology, is pleased to announce that it has closed its 2020 cash capital offering of ordinary shares in Taiwan, with the record date of June 30, 2020.